Larimar Therapeutics shares are trading higher after JMP Securities maintained a Market Outperform rating and raised its price target from $17 to $25.
Portfolio Pulse from Benzinga Newsdesk
Larimar Therapeutics' stock price increased following JMP Securities' decision to maintain a Market Outperform rating and raise its price target from $17 to $25.
February 13, 2024 | 4:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Larimar Therapeutics' stock price is likely to experience a short-term increase following JMP Securities' positive rating and raised price target.
Analyst ratings and price target adjustments are significant indicators of a stock's potential performance. JMP Securities' decision to maintain a Market Outperform rating and increase the price target for Larimar Therapeutics from $17 to $25 signals strong confidence in the company's future prospects. This endorsement is likely to positively influence investor sentiment and drive up the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100